CIRCULATING INSULIN-LIKE GROWTH FACTOR (IGF)-ASSOCIATED PROTEINS FOR THE DETECTION OF LUNG CANCER

摘要

A method and a kit for assessing risk of lung cancer versus benign disease in a subject are provided. The method includes obtaining a biological sample from the subject and determining a measurement for a panel of biomarkers in the biological sample. The panel includes at least one biomarker selected from the group consisting of IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, IGFBP-6, IGFBP-7, IGF-1, and IGF-2 and at least one biomarker selected from the group consisting of IL-6, IL-1 ra, IL-10, SDF-Ια+β, TNF-a, MIP-1a, slL-2Ra, CA-125, Eotaxin, OPN, sEGFR, and sE-Selectin. The method further includes comparing the measurement to a reference profile for the panel of biomarkers, sorting the subject into a stratification group and determining whether the subject is at risk for lung cancer based on the stratification group.